News

Epix submitted the appeal to the FDA’s Office of New Drugs (OND) on June 30, 2006 in response to two prior approvable letters for Vasovist. Epix were also

The study of 104 patients showed a statistically significant reduction in the number of brain lesions observed on serial MRI scans of the brain in the Rituxan-treated group

“The initiation of this pivotal trial is an important milestone in the development of PDX and has the potential to be a significant driver of the company’s future

The contract is under a master agreement with the National Institutes of Health and funded by the National Institute of Allergy and Infectious Diseases. Current vaccine production methods

Funded by the US Agency for International Development (USAID), the trial was part of an international effort to evaluate microbicides as a tool to reduce the risk of

Under the terms of the transaction, Mylan will purchase 51.5% of Matrix’s shares and then make an open offer to Matrix’s remaining shareholders to acquire up to an

The new agreement, which expands a previous deal, is for all of the Mayo Clinic’s non-prescription intranasal treatments for the condition which work by suppressing non-invasive (so-called “saprophytic”)

In preclinical studies, Heat Shock Protein 90 (Hsp90) and the Hedgehog pathway appear to be implicated in the growth and survival of a broad range of blood-related and

The Orapred product line, which includes Orapred ODT and Orapred is marketed by Alliant Pharmaceuticals under a North American license and acquisition agreement entered into on March 15,